Prescription VR Therapeutics Market to Reach $371.3 Million by 2034 as CAGR Hits 41.2%
Updated
Updated · Fortune Business Insights · Jun 25
Prescription VR Therapeutics Market to Reach $371.3 Million by 2034 as CAGR Hits 41.2%
1 articles · Updated · Fortune Business Insights · Jun 25
Summary
$371.3 million by 2034 is the new forecast for the global prescription VR therapeutics market, up from $12.1 million in 2025 and $23.5 million expected in 2026.
Fortune Business Insights said demand is being driven by chronic disease prevalence, interest in non-invasive treatment, expanding healthcare infrastructure, and broader regulatory validation of VR as a medical device.
AI-enabled personalization and remote monitoring are emerging as key growth themes, with vendors using patient-level data to tailor therapy, track outcomes, and support value-based care models.
Limited reimbursement remains the main brake on adoption because pricing, coding, coverage, headset costs, and home-use support make commercialization difficult.
North America led the market at $11.3 million in 2025, while pain management held a 70.6% share and homecare remained the dominant care setting.